EP2305635A3 - Tartrate du formotérol, procédé et polymorphe - Google Patents

Tartrate du formotérol, procédé et polymorphe Download PDF

Info

Publication number
EP2305635A3
EP2305635A3 EP10178918A EP10178918A EP2305635A3 EP 2305635 A3 EP2305635 A3 EP 2305635A3 EP 10178918 A EP10178918 A EP 10178918A EP 10178918 A EP10178918 A EP 10178918A EP 2305635 A3 EP2305635 A3 EP 2305635A3
Authority
EP
European Patent Office
Prior art keywords
polymorph
formoterol tartrate
formoterol
tartrate process
tartrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10178918A
Other languages
German (de)
English (en)
Other versions
EP2305635B1 (fr
EP2305635A2 (fr
Inventor
Gerald J. Tanoury
Chris H. Senanayake
Donald W. Kessler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21892899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2305635(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of EP2305635A2 publication Critical patent/EP2305635A2/fr
Publication of EP2305635A3 publication Critical patent/EP2305635A3/fr
Application granted granted Critical
Publication of EP2305635B1 publication Critical patent/EP2305635B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
EP10178918.8A 2001-11-09 2002-10-23 Tartrate du formoterol, procede et polymorphe Expired - Lifetime EP2305635B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/037,183 US6472563B1 (en) 2001-11-09 2001-11-09 Formoterol tartrate process and polymorph
EP02786502A EP1446380B1 (fr) 2001-11-09 2002-10-23 Procede d'elaboration de formoterol tartrate et polymorphe
EP09172739A EP2165999A1 (fr) 2001-11-09 2002-10-23 Tartrate du formotérol: Procédé et Polymorphe

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
EP02786502A Division EP1446380B1 (fr) 2001-11-09 2002-10-23 Procede d'elaboration de formoterol tartrate et polymorphe
EP09172739A Division EP2165999A1 (fr) 2001-11-09 2002-10-23 Tartrate du formotérol: Procédé et Polymorphe
EP02786502.1 Division 2002-10-23
EP09172739.6 Division 2009-10-12

Publications (3)

Publication Number Publication Date
EP2305635A2 EP2305635A2 (fr) 2011-04-06
EP2305635A3 true EP2305635A3 (fr) 2011-07-20
EP2305635B1 EP2305635B1 (fr) 2018-06-13

Family

ID=21892899

Family Applications (3)

Application Number Title Priority Date Filing Date
EP09172739A Ceased EP2165999A1 (fr) 2001-11-09 2002-10-23 Tartrate du formotérol: Procédé et Polymorphe
EP10178918.8A Expired - Lifetime EP2305635B1 (fr) 2001-11-09 2002-10-23 Tartrate du formoterol, procede et polymorphe
EP02786502A Expired - Lifetime EP1446380B1 (fr) 2001-11-09 2002-10-23 Procede d'elaboration de formoterol tartrate et polymorphe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09172739A Ceased EP2165999A1 (fr) 2001-11-09 2002-10-23 Tartrate du formotérol: Procédé et Polymorphe

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP02786502A Expired - Lifetime EP1446380B1 (fr) 2001-11-09 2002-10-23 Procede d'elaboration de formoterol tartrate et polymorphe

Country Status (13)

Country Link
US (10) US6472563B1 (fr)
EP (3) EP2165999A1 (fr)
JP (1) JP4271574B2 (fr)
AT (1) ATE450497T1 (fr)
AU (2) AU2002349914B2 (fr)
CA (1) CA2477642C (fr)
CY (1) CY1109832T1 (fr)
DE (1) DE60234629D1 (fr)
DK (1) DK1446380T3 (fr)
ES (2) ES2336436T3 (fr)
PT (1) PT1446380E (fr)
SI (1) SI1446380T1 (fr)
WO (1) WO2003042165A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
WO2005019227A1 (fr) * 2003-08-22 2005-03-03 Orchid Chemicals & Pharmaceuticals Ltd Procede de preparation d'un antibiotique a base de cephalosporine
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US7718822B2 (en) * 2007-08-28 2010-05-18 Sepracor Inc. Carbamate Stereoisomer
US8501994B2 (en) 2007-08-28 2013-08-06 Sunovion Pharmaceuticals Inc. Acetamide stereoisomer
CN101393186A (zh) * 2007-09-21 2009-03-25 北京德众万全药物技术开发有限公司 一种hplc法分离分析酒石酸福莫特罗手性异构体的方法
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2009106997A2 (fr) * 2008-02-28 2009-09-03 Actavis Group Ptc Ehf L-(+)-tartrate d’arformotérol amorphe
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
WO2010128355A2 (fr) 2008-12-26 2010-11-11 Actavis Group Ptc Ehf Procédés améliorés de préparation d'arformotérol pratiquement pur et de ses intermédiaires
WO2011038872A1 (fr) * 2009-10-02 2011-04-07 Chiesi Farmaceutici S.P.A. Formulations d'aérosol pharmaceutique de formotérol et de dipropionate de béclométasone
IT1399912B1 (it) * 2010-04-29 2013-05-09 Lundbeck Pharmaceuticals Italy S Pa Processo di preparazione di ritodrina cloridrato.
AU2012311293B2 (en) 2011-09-19 2014-02-20 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
EP2825525B1 (fr) * 2012-03-12 2018-04-25 Laboratorios Lesvi S.L. Nouvelle forme polymorphe d'un agoniste du récepteur adrénergique bêta-2 à action prolongée
CN105026369A (zh) 2013-02-28 2015-11-04 德米拉股份有限公司 格隆铵盐
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
CN105431409A (zh) * 2013-05-17 2016-03-23 格伦马克制药有限公司 制备阿福特罗或其盐的方法
CN107151219A (zh) * 2017-05-23 2017-09-12 北京万全德众医药生物技术有限公司 酒石酸阿福特罗的精制方法
CN111909049B (zh) * 2020-09-03 2023-04-25 扬州中宝药业股份有限公司 一种酒石酸阿福特罗精制的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268533B1 (en) * 1996-11-11 2001-07-31 Sepracor Inc. Formoterol process

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2005492A6 (es) 1987-12-23 1989-03-01 Lasa Lab Procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2((2- (4-metoxifenil)-1metiletil)amino)etil)fenil)foramida (i).
ES2031407A6 (es) 1988-10-05 1992-12-01 Lasa Lab Mejoras introducidas en el objeto de la patente principal n{ 8703715 por: procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2-((2-(4-metoxifenil)-1-metiletil)amino)etil)fenil)formamida".
SE8901060D0 (sv) 1989-03-28 1989-03-28 Draco Ab New compounds
SE9003057D0 (sv) 1990-09-26 1990-09-26 Astra Ab New process
US5434304A (en) * 1990-09-26 1995-07-18 Aktiebolaget Astra Process for preparing formoterol and related compounds
NZ509489A (en) * 1998-08-04 2002-10-25 Jago Res A Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil
US6472563B1 (en) 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268533B1 (en) * 1996-11-11 2001-07-31 Sepracor Inc. Formoterol process

Also Published As

Publication number Publication date
CA2477642C (fr) 2014-02-11
EP1446380B1 (fr) 2009-12-02
US7964753B2 (en) 2011-06-21
US7479572B2 (en) 2009-01-20
US6472563B1 (en) 2002-10-29
ES2336436T3 (es) 2010-04-13
JP4271574B2 (ja) 2009-06-03
US20080114187A1 (en) 2008-05-15
US20100204336A1 (en) 2010-08-12
EP2305635B1 (fr) 2018-06-13
SI1446380T1 (sl) 2010-03-31
US20100249459A1 (en) 2010-09-30
EP1446380A1 (fr) 2004-08-18
US20120108670A1 (en) 2012-05-03
US7342132B2 (en) 2008-03-11
US20030149304A1 (en) 2003-08-07
DE60234629D1 (de) 2010-01-14
ES2685100T3 (es) 2018-10-05
PT1446380E (pt) 2010-01-07
ATE450497T1 (de) 2009-12-15
EP2165999A1 (fr) 2010-03-24
US20060264507A1 (en) 2006-11-23
US20040176450A1 (en) 2004-09-09
AU2002349914B2 (en) 2008-09-04
US20090156862A1 (en) 2009-06-18
WO2003042165A1 (fr) 2003-05-22
US20050148667A1 (en) 2005-07-07
US7145036B2 (en) 2006-12-05
EP2305635A2 (fr) 2011-04-06
US8110706B2 (en) 2012-02-07
AU2008253696A1 (en) 2009-01-08
JP2005509025A (ja) 2005-04-07
US6720453B2 (en) 2004-04-13
CY1109832T1 (el) 2014-09-10
DK1446380T3 (da) 2010-01-04
US7732641B2 (en) 2010-06-08
CA2477642A1 (fr) 2003-05-22
AU2008253696B2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
EP2305635A3 (fr) Tartrate du formotérol, procédé et polymorphe
CA2333004A1 (fr) Polymorphes du formoterol
MXPA05003093A (es) Diaril eteres como antagonistas de receptor opiode.
CA2431068A1 (fr) Formes cristallines d'atorvastatine
IL160440A (en) Dihydropteridinones, method for producing the same and the use thereof as medicaments
CA2450093A1 (fr) Polymorphe stable de flibanserine, procede de preparation associe et utilisation dudit polymorphe dans la preparation de medicaments
HK1073295A1 (en) Acetyl l-carnitine acid fumarate and process for preparing the same
WO2002066429A8 (fr) Procede de production d'hydrochlorure fexofenadine non hydrate et nouvelle forme cristalline ainsi obtenue
EP1532131A4 (fr) Composes du type motilide
WO2003048082A3 (fr) Base cristalline de venlafaxine et nouveaux polymorphes du chlorhydrate de venlafaxine et procedes de preparation
CA2462998A1 (fr) Nouveaux composes oestrogeniques
MXPA04005305A (es) Nuevo polimorfo cristalino de clorhidrato de venlafaxina y metodos para preparacion del mismo.
AU2003298178A1 (en) Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea
WO2005023808A3 (fr) Synthèse
IL157709A0 (en) Process for the preparation of 1,2-benzisoxazole-3-acetic acid
AU2001248998A1 (en) Method for the preparation of (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1- naphthalenemethanamine (terbinafine)
AU2003252467A1 (en) Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
AU2003240634A1 (en) Method for producing bicalutamide
WO2002053537A8 (fr) Procede de preparation de (?)-trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
AU2002310949A1 (en) Method of producing N-substituted 2,6-dialkyl morpholines
WO2007046001A3 (fr) Procede d'elaboration de 3,3-diarylpropylamines
WO2004089965A3 (fr) Procede et produit
WO2002085877A3 (fr) Procedes et intermediaires de preparation de benzyl epoxydes
EP1295864A4 (fr) Procede de preparation de 1,5-diaminonaphtalenes
WO2005058896A3 (fr) Synthese

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2165999

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1446380

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KESSLER, DONALD W.

Inventor name: SENANAYAKE, CHRIS H.

Inventor name: TANOURY, GERALD, J.

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20120120

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SUNOVION PHARMACEUTICALS INC.

17Q First examination report despatched

Effective date: 20160418

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20180119

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 2165999

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1446380

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1008376

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60249479

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2685100

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20181005

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180613

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180913

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180914

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1008376

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60249479

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181023

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180613

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20211027

Year of fee payment: 20

Ref country code: ES

Payment date: 20211102

Year of fee payment: 20

Ref country code: DE

Payment date: 20211027

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20211021

Year of fee payment: 20

Ref country code: FR

Payment date: 20211025

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60249479

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20221031

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20221022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20221022

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20221024